NextCure (NextCure) Valuation Rank

View and export this data going back to 2019. Start your Free Trial

What is NextCure Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

Three factors:
- Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
- Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
- Industry relative valuation
Companies without enough data is not ranked
Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

NextCure Valuation Rank Related Terms

Thank you for viewing the detailed overview of NextCure's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

NextCure (NextCure) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NextCure Inc (NAS:NXTC) » Definitions » Valuation Rank

Comparable Companies

Traded in Other Exchanges

2US:Germany

Address

9000 Virginia Manor Road, Suite 200, Beltsville, MD, USA, 20705

Website

https://www.nextcure.com

NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include NC410 a fusion protein of LAIR-2, a naturally occurring soluble version of and decoy protein for LAIR-1 and is designed to block immune suppression mediated by LAIR-1, NC762 a monoclonal antibody that binds specifically to human B7 homolog 4 protein, or B7-H4, a protein expressed on multiple tumor types, and NC525 (LAIR-1 mAb) is a novel LAIR-1 antibody that selectively targets Acute Myeloid Leukemia, or AML, blast cells, and leukemic stem cells, or LSCs.

Executives

Anne Elizabeth Borgman	director	9000 VIRGINIA MANOR ROAD, SUITE 200, BELTSVILLE MD 20705
Ellen Feigal	director	C/O XENCOR INC., 111 WEST LEMON AVENUE, MONROVIA CA 91016
Kevin G. Shaw	officer: Sr VP, Legal Affairs	9000 VIRGINIA MANOR ROAD, SUITE 200, BELTSVILLE MD 20705
Sourav Kundu	officer: Sr VP, Dev. & Mfg.	9000 VIRGINIA MANOR ROAD, SUITE 200, BELTSVILLE MD 20705
Han Myint	officer: Chief Medical Officer	C/O NEXTCURE, INC., 9000 VIRGINIA MANOR ROAD, SUITE 200, BELTSVILLE MD 20705
Timothy Mayer	officer: Chief Operating Officer	C/O NEXTCURE, INC., 9000 VIRGINIA MANOR ROAD, SUITE 200, BELTSVILLE MD 20705
Sol Langermann	officer: Chief Scientific Officer	C/O NEXTCURE, INC., 9000 VIRGINIA MANOR ROAD, SUITE 200, BELTSVILLE MD 20705
Steven P. Cobourn	officer: Chief Financial Officer	C/O NEXTCURE, INC., 9000 VIRGINIA MANOR ROAD, SUITE 200, BELTSVILLE MD 20705
Linda Liu	officer: SVP, Research	C/O NEXTCURE, INC., 9000 VIRGINIA MANOR ROAD, SUITE 200, BELTSVILLE MD 20705
Michael Richman	director, officer: President & CEO	2635 TECHNOLOGY FOREST BLVD., HOUSTON TX 77381
John G Houston	director	C/O ARVINAS, INC., 5 SCIENCE PARK, 395 WINCHESTER AVE., NEW HAVEN CT 06511
Garry A Nicholson	director	C/O TESARO, INC., 1000 WINTER STREET, SUITE 3300, WALTHAM MA 02451
Anand Mehra	10 percent owner	3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025
Michael Powell	10 percent owner	3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025
James Healy	10 percent owner	3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025